As part of the pharma deals, Athera grants to Boehringer Ingelheim, a big pharma, an exclusive option to acquire the entire cardiovascular antibody program.
Karolinska Development AB owns 65% of Athera Biotechnologies AB.
Athera’s fully-human monoclonal antibody is intended for the treatment of patients with cardiovascular disease, who are at an increased risk of secondary events and death.
Pursuant to the terms of the pharma deals option agreement, Athera will conduct defined preclinical development and a Phase I study for the lead antibody and, following the completion of such study, Boehringer Ingelheim will have an exclusive option to acquire substantially all of Athera’s assets and rights relating to the program.
In exchange for Athera’s granting of the option in the pharma deals, Boehringer Ingelheim will pay an option fee.
The size of the fee and the other terms of the option are not being disclosed but this transaction is in line with market average terms for programs at similar stages of development.
Report: Partnering Deals and Alliances with Boehringer Ingelheim
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity